Currently, there are 821.41M common shares owned by the public and among those 816.23M shares have been available to trade.
The company’s stock has a 5-day price change of -2.02% and 6.49% over the past three months. CL shares are trading 26.19% year to date (YTD), with the 12-month market performance up to 30.81% higher. It has a 12-month low price of $67.62 and touched a high of $104.15 over the same period. CL has an average intraday trading volume of 4.07 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.75%, 3.15%, and 15.12% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Colgate-Palmolive Co. (NYSE: CL) shares accounts for 86.93% of the company’s 821.41M shares outstanding.
It has a market capitalization of $82.19B and a beta (3y monthly) value of 0.39. The stock’s trailing 12-month PE ratio is 29.24, while the earnings-per-share (ttm) stands at $3.44. The company has a PEG of 3.42 and a Quick Ratio of 0.70 with the debt-to-equity ratio at 70.54. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.60% over the week and 1.93% over the month.
Earnings per share for the fiscal year are expected to increase by 10.54%, and 8.93% over the next financial year. EPS should grow at an annualized rate of 8.54% over the next five years, compared to 0.18% over the past 5-year period.
Jefferies coverage for the Colgate-Palmolive Co. (CL) stock in a research note released on July 24, 2024 offered a Hold rating with a price target of $95. TD Cowen was of a view on July 23, 2024 that the stock is Buy, while Exane BNP Paribas gave the stock Outperform rating on June 24, 2024, issuing a price target of $109. Goldman on their part issued Buy rating on March 01, 2024.
